Givosiran

(Givlaari®)

Givlaari®

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 189 mg/mL)
Drug ClassAminolevulinate synthase 1-directed small interfering RNA
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with acute hepatic porphyria (AHP).